CURRENT
ISSUE
1583

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available vaccines and recommendations for specific patient populations for the 2019-2020 season are listed in Tables 2 and 3.

TIMING — In the US, influenza vaccine should be offered by the end of October and continue to be offered for as long as influenza is circulating in the community. In most adults, serum antibody levels peak about two weeks after vaccination.Continue reading

More from Issue 1583
Previous Issue: 1582      October 7, 2019
Coming Soon
Drugs for Type 2 Diabetes
Turmeric Supplements
Upadacitinib (Rinvoq) for Rheumatoid Arthritis
Darolutamide (Nubeqa) for Prostate Cancer
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
Advance Release
ADVANCE
RELEASE

The FDA has approved a new formulation of glucagon (Gvoke – Xeris) for subcutaneous treatment of severe hypoglycemia in patients ≥2 years old with diabetes. Conscious patients with symptoms of hypoglycemia can take oral glucose. Glucagon is usually administered by a caregiver to an unresponsive patient. The new formulation is available in a single-use prefilled syringe (Gvoke PFS) and is expected to become available in a single-use auto-injector (Gvoke HypoPen) in 2020. Unlike previously available injectable glucagon products (Glucagon Emergency Kit, and others), Gvoke does not require reconstitution before administration. A glucagon nasal ... Continue reading